The serotonin transporter gene and effectiveness of SSRIs

References

• Bauwens F, Tracj A, Pardoen D, Vander Elst M, Mendlewicz J. Social adjustment of remitted bipolar and unipolar out-patients. A comparison with age- and sex-matched controls. Br. J. Psychiatry159, 239–244 (1991).
   PubMedGoogle Scholar
• Pincus HA, Pettit AR. The societal costs of chronic major depression. J. Clin. Psychiatry62(Suppl. 6), 5–9 (2001).
   PubMed Web of Science ®Google Scholar
• Rice DP. The economic impact of schizophrenia. J. Clin. Psychiatry60(Suppl. 1), 4–6; discussion 28–30 (1999).
   PubMed Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J. Biol. Psychiatry3(3), 115–124 (2002).
   PubMedGoogle Scholar
• Geddes JR, Freemantle N, Mason J et al. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst. Rev.2, CD001851 (2000).
   PubMedGoogle Scholar
• Goodnick PJ. Predictors of tReatment Response In Mood Disorders. Clinical Practice. American Psychiatric Press, Washington, DC, USA. (1996).
   Google Scholar
• Esposito K, Goodnick P. Predictors of response in depression. Psychiatr. Clin. North Am.26(2), 353–365 (2003).
   PubMedGoogle Scholar
• Nierenberg AA. Predictors of response to antidepressants general principals and clinical implications. Psychiatr. Clin. North Am.26, 345–352 (2003).
   PubMed Web of Science ®Google Scholar
• Orsini A. Antidepressant responses and segregation analyses in affective families. In: Anxious Depression: Assessment and Treatment. Racagni G, Smeraldi E (Eds). Raven Press, NY, USA (1987).
   Google Scholar
• Sederer LI. Depression. In: Inpatients Psychiatry Diagnosis and Treatment. Sederer LI (Ed). William & Wilkins, MD, USA (1986).
   Google Scholar
• Berrettini W. Progress and pitfalls: bipolar molecular linkage studies. J. Affect. Disord.50(2–3), 287–297 (1998).
   PubMedGoogle Scholar
• Pare CM, Mack JW. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J. Med. Genet.8(3), 306–309 (1971).
   PubMedGoogle Scholar
• Serretti A, Artioli P, Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet. Genomics15(2), 61–67 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Fornal CA. Serotonin and behavior. A general hypothesis. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds). Raven Press, NY, USA 461–469 (1995).
   Google Scholar
• Maes M, Meltzer HY. The serotonin hypothesis of major depression. In: Psychopharmacology: The Fourth Generation of Progress. Bloom FE, Kupfer DJ (Eds). Raven Press, NY, USA. 933–944 (1995).
   Google Scholar
• Holmes A, Murphy DL, Crawley JN. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol. Psychiatry54(10), 953–959 (2003).
   PubMed Web of Science ®Google Scholar
• Holmes A, Yang RJ, Lesch KP, Crawley JN, Murphy DL. Mice lacking the serotonin transporter exhibit 5-HT1A receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology28(12), 2077–2088 (2003).
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S, Bauman AL, Moore KR et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl Acad. Sci. USA90(6), 2542–2546 (1993).
   PubMed Web of Science ®Google Scholar
• Lesch KP, Balling U, Gross J et al. Organization of the human serotonin transporter gene. J. Neural. Transm. Gen. Sect.95(2), 157–162 (1994).
   PubMed Web of Science ®Google Scholar
• Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem.66(6), 2621–2624 (1996).
   PubMed Web of Science ®Google Scholar
• Eichhammer P, Langguth B, Wiegand R et al. Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI). Psychopharmacology (Berl.)166(3), 294–297 (2003).
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Zanardi R, Benedetti F et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry3(6), 508–511 (1998).
   PubMed Web of Science ®Google Scholar
• Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J. Clin. Psychopharmacol.20(1), 105–107 (2000).
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology23(5), 587–590 (2000).
   PubMed Web of Science ®Google Scholar
• Zanardi R, Rossini D, Serretti A. Problems with ensuring double blind – replay. J. Clin. Psychiatry62(4), 296 (2001).
   PubMedGoogle Scholar
• Rausch JL, Johnson ME, Fei Y-J et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol. Psychiatry51(9), 723–732 (2002).
   PubMed Web of Science ®Google Scholar
• Arias B, Catalan R, Gasto C et al. Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram. In: World Federation of Societies of Biological Psychiatry. The World Journal of Biological Psychiatry, Berlin, Germany 9S (2001).
   Google Scholar
• Joyce PR, Mulder RT, Luty SE et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol.6(4), 339–346 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry61(11), 1163–1169 (2004).
   PubMed Web of Science ®Google Scholar
• Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, isassociated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl.)174(4), 525–529 (2004).
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry7(10), 1115–1119 (2002).
   PubMed Web of Science ®Google Scholar
• Lee MS, Lee HY, Lee HJ, Ryu SH. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr. Genet.14(2), 111–115 (2004).
   PubMed Web of Science ®Google Scholar
• Kato M, Ikenaga Y, Wakeno M et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int. Clin. Psychopharmacol.20(3), 151–156 (2005).
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Wakeno M et al. Effects of the serotonin type 2A, 3–3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology53(4), 186–195 (2006).
   PubMed Web of Science ®Google Scholar
• Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J.6(1), 27–33 (2006).
   PubMed Web of Science ®Google Scholar
• Kim DK, Lim SW, Lee S et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport11(1), 215–219 (2000).
   PubMed Web of Science ®Google Scholar
• Yoshida K, Ito K, Sato K et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry26(2), 383–386 (2002).
   PubMed Web of Science ®Google Scholar
• Kim H, Lim S-W, Kim S et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA296(13), 1609–1618 (2006).
   PubMed Web of Science ®Google Scholar
• Ng CH, Easteal S, Tan S et al. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog. Neuropsychopharmacol. Biol. Psychiatry30(5), 953–957 (2006).
   PubMed Web of Science ®Google Scholar
• Serretti A, Mandelli L, Lorenzi C et al. Serotonin transporter gene influences the time course of improvement of “core” depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Res.149(1–3), 185–193 (2007).
   PubMedGoogle Scholar
• Kraft JB, Peters EJ, Slager SL et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol. Psychiatry61(6), 734–742 (2006).
   PubMedGoogle Scholar
• Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr. Clin. North Am.26(2), 457–494 (2003).
   PubMed Web of Science ®Google Scholar
• Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Hu XZ, Rush AJ, Charney D et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry64(7), 783–792 (2007).
   PubMed Web of Science ®Google Scholar
• Perlis R, Smoller J, Wan Y et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. In: Pharmacogenetics in Psychiatry Meeting. Hospital, TZH, NY, USA (2003).
   Google Scholar
• Takahashi H, Yoshida K, Ito K et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur. Neuropsychopharmacol.12(5), 477–481 (2002).
   PubMed Web of Science ®Google Scholar
• Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch. Gen. Psychiatry58, 539–544 (2001).
   PubMed Web of Science ®Google Scholar
• Masoliver E, Menoyo A, Perez V et al. Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder. Psychiatr. Genet.16(1), 25–29 (2006).
   PubMed Web of Science ®Google Scholar
• Rousseva A, Henry C, Van Den Bulke D et al. Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J.3(2), 101–104 (2003).
   PubMed Web of Science ®Google Scholar
• Serretti A, Artioli P, Zanardi R et al. Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl.)174(4), 504–511 (2004).
   PubMedGoogle Scholar
• Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry12(3), 247–257 (2007).
   PubMed Web of Science ®Google Scholar
• Lesch KP. Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs. Eur. Neuropsychopharmacol.11(6), 457–474 (2001).
   PubMed Web of Science ®Google Scholar
• Hranilovic D, Stefulj J, Schwab S et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol. Psychiatry55(11), 1090–1094 (2004).
   PubMed Web of Science ®Google Scholar
• Greenberg BD, Tolliver TJ, Huang SJ et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet.88(1), 83–87 (1999).
   PubMed Web of Science ®Google Scholar
• Javors MA, Seneviratne C, Roache JD et al. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Prog. Neuropsychopharmacol. Biol. Psychiatry29(1), 7–13 (2005).
   PubMedGoogle Scholar
• Teshima KM, Przeworski M. Directional positive selection on an allele of arbitrary dominance. Genetics172(1), 713–718 (2006).
   PubMedGoogle Scholar
• Williams NM, O’Donovan MC, Owen MJ. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr. Bull.31(4), 800–805 (2005).
   PubMed Web of Science ®Google Scholar
• Allison DB, Thiel B, Stjean P et al. Multiple phenotype modeling in gene-mapping studies of quantitative traits – power advantages. Am. J. Hum. Genet.63(4), 1190–1201 (1998).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol. Psychiatry5(1), 32–38 (2000).
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Serretti A, Artioli P, Lorenzi C, Catalano M. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr. Genet.16(4), 153–158 (2006).
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry9(9), 879–889 (2004).
   PubMed Web of Science ®Google Scholar
• Kraft JB, Slager SL, McGrath PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol. Psychiatry58(5), 374–381 (2005).
   PubMed Web of Science ®Google Scholar
• Hu XZ, Lipsky RH, Zhu G et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive–compulsive disorder. Am. J. Hum. Genet.78(5), 815–826 (2006).
   PubMed Web of Science ®Google Scholar
• Kunugi H, Hattori M, Kato T et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry2(6), 457–462 (1997).
   PubMed Web of Science ®Google Scholar
• Serretti A, Zanardi R, Rossini D et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry6, 586–592 (2001).
   PubMed Web of Science ®Google Scholar
• Kendler KS. “A gene for” the nature of gene action in psychiatric disorders. Am. J. Psychiatry162(7), 1243–1252 (2005).
   PubMed Web of Science ®Google Scholar
• Serretti A, Calati R, Mandelli L, De Ronchi D. Serotonin transporter gene variants and behaviour: a comprehensive review. Curr. Drug Targets7, 1659–1669 (2006).
   PubMed Web of Science ®Google Scholar
• Veenstra-VanderWeele J, Anderson GM, Cook EH. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur. J. Pharmacol.410(2–3), 165–181 (2000).
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am. J. Psychiatry158(8), 1265–1270 (2001).
   PubMed Web of Science ®Google Scholar
• Rice JP, Rochberg N, Endicott J, Lavori PW, Miller C. Stability of psychiatric diagnoses. An application to the affective disorders. Arch. Gen. Psychiatry49(10), 824–830 (1992).
   PubMedGoogle Scholar
• Tsuang M, Faraone S. The Genetics of Mood Disorders.The Johns Hopkins University Press, MD, USA (1990).
   Google Scholar
• Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am. J. Psychiatry159(3), 469–473 (2002).
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry9(9), 879–889 (2004).
   PubMed Web of Science ®Google Scholar
• Mitchell AJ. Two-week delay in onset of action of antidepressants: new evidence. Br. J. Psychiatry188, 105–106 (2006).
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J. Clin. Psychiatry66(2), 159–166; quiz 147, 273–154 (2005).
   PubMedGoogle Scholar
• Meyers BS, Sirey JA, Bruce M et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch. Gen. Psychiatry59(8), 729–735 (2002).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am. J. Psychiatry157(Suppl. 4), 1–45 (2000).
   Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry3(1), 5–43 (2002).
   PubMedGoogle Scholar
• Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr. Scand.101(5), 354–359 (2000).
   PubMed Web of Science ®Google Scholar
• Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur. Arch. Psychiatry Clin. Neurosci.255(6), 387–400 (2005).
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Bies RR, Smith GS, Pollock BG. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J. Psychopharmacol.20(Suppl. 4), 33–40 (2006).
   PubMed Web of Science ®Google Scholar
• Serretti A, Cusin C, Benedetti F et al. Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet.137(1), 36–39 (2005).
   Web of Science ®Google Scholar
• Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science274(5292), 1527–1531 (1996).
   PubMed Web of Science ®Google Scholar
• Melke J, Landen M, Baghei F et al. Serotonin transporter gene polymorphisms are associated with anxiety-related personality traits in women. Am J. Med. Genet.105(5), 458–463 (2001).
   PubMed Web of Science ®Google Scholar
• Bailey DS, Bondar A, Furness LM. Pharmacogenomics – it’s not just pharmacogenetics. Curr. Opin. Biotechnol.9(6), 595–601 (1998).
   PubMed Web of Science ®Google Scholar
• Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat. Genet.21(Suppl. 1), 33–37 (1999).
   PubMed Web of Science ®Google Scholar
• Kao CM. Functional genomic technologies: creating new paradigms for fundamental and applied biology. Biotechnol. Prog.15(3), 304–311 (1999).
   PubMed Web of Science ®Google Scholar
• Chen B, Wang JF, Sun X, Young LT. Regulation of GAP-43 expression by chronic desipramine treatment in rat cultured hippocampal cells. Biol. Psychiatry53(6), 530–537 (2003).
   PubMedGoogle Scholar
• Drigues N, Poltyrev T, Bejar C, Weinstock M, Youdim MB. cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs. J. Neural Transm.110(12), 1413–1436 (2003).
   PubMedGoogle Scholar
• Landgrebe J, Welzl G, Metz T et al. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J. Psychiatr Res.36(3), 119–129 (2002).
   PubMedGoogle Scholar
• Yamada M, Yamada M, Higuchi T. Antidepressant-elicited changes in gene expression: remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog. Neuropsychopharmacol. Biol. Psychiatry29(6), 999–1009 (2005).
   PubMedGoogle Scholar
• Palotas A, Puskas LG, Kitajka K et al. The effect of citalopram on gene expression profile of Alzheimer lymphocytes. Neurochem. Res.29(8), 1563–1570 (2004).
   PubMed Web of Science ®Google Scholar
• Lachman HM, Kelsoe JR, Remick RA et al. Linkage studies suggest a possible locus for bipolar disorder near the velo-cardio-facial syndrome region on chromosome 22. Am. J. Med. Genet.74, 121–128 (1997).
   PubMedGoogle Scholar
• Niculescu AB III, Segal DS, Kuczenski R et al. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol. Genomics4(1), 83–91 (2000).
   PubMed Web of Science ®Google Scholar
• Alda M. Pharmacogenetics of lithium response in bipolar disorder. J. Psychiatry Neurosci.24(2), 154–158 (1999).
   PubMed Web of Science ®Google Scholar
• Bellivier F, Leroux M, Henry C et al. Serotonin transporter gene polymorphism influences age at onset in patients with bipolar affective disorder. Neurosci. Lett.334(1), 17–20 (2002).
   PubMedGoogle Scholar
• Nobile M, Cataldo MG, Giorda R et al. A case–control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol. Psychiatry56(4), 292–295 (2004).
   PubMedGoogle Scholar
• Cusin C, Serretti A, Lattuada E et al. Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. J. Psychiatric Res.35(4), 217–223 (2001).
   PubMedGoogle Scholar
• Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science301(5631), 386–389 (2003).
   PubMed Web of Science ®Google Scholar
• Park JW, Kim JS, Lee HK, Kim YI, Lee KS. Serotonin transporter polymorphism and harm avoidance personality in chronic tension-type headache. Headache44(10), 1005–1009 (2004).
   PubMedGoogle Scholar
• Feinn R, Nellissery M, Kranzler HR. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am. J. Med. Genet. B NeuroPsychiatr. Genet.133(1), 79–84 (2005).
   Google Scholar
• Kremer I, Bachner-Melman R, Reshef A et al. Association of the serotonin transporter gene with smoking behavior. Am. J. Psychiatry162(5), 924–930 (2005).
   PubMed Web of Science ®Google Scholar
• Yeo A, Boyd P, Lumsden S et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut53(10), 1452–1458 (2004).
   PubMed Web of Science ®Google Scholar
• Matsushita S, Suzuki K, Murayama M et al. Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. Am. J. Med. Genet. B NeuroPsychiatr. Genet.128(1), 114–117 (2004).
   Google Scholar
• Steiger H, Joober R, Israel M et al. The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet[3H-] paroxetine binding in bulimic syndromes. Int. J. Eat. Disord.37(1), 57–60 (2005).
   PubMed Web of Science ®Google Scholar
• Courtet P, Baud P, Abbar M et al. Association between violent suicidal behavior and the low activity allele of the serotonin transporter gene. Mol. Psychiatry6(3), 338–341 (2001).
   PubMed Web of Science ®Google Scholar
• Bartlett CW, Gharani N, Millonig JH, Brzustowicz LM. Three autism candidate genes: a synthesis of human genetic analysis with other disciplines. Int. J. Dev. Neurosci.23(2–3), 221–234 (2005).
   PubMedGoogle Scholar
• Bobb AJ, Castellanos FX, Addington AM, Rapoport JL. Molecular genetic studies of ADHD: 1991 to 2004. Am. J. Med. Genet. B NeuroPsychiatr. Genet.132(1), 109–125 (2005).
   Google Scholar